To establish the effective protocol for generating ex vivo triple negative breast cancer (TNBC)-specific effector T cells by self-differentiated DCs (SD-DCs) presenting specific TNBC antigens (SMART-DCs)
Secondary objectives
1. To find the incidence of mesothelin and nucleolin TNBC antigens in clinical samples of Thai TNBC patients and their clinicopathological correlation
2. To establish the effective production of mesothelin- or nucleolin-presented SMART-DCs and their potential to produce TNBC-specific effector T cells
3. To investigate the killing effect of TNBC-specific effector T cells patient derived TNBC cells
4. To find the immunosuppressive effect of CAFs-derived substances and how to inhibit
